Related Experiment Video
Updated: Jan 11, 2026
Mouse Models Of Helicobacter Infection And Gastric Pathologies
Published on: October 18, 2018
Integrated multi-omics and molecular docking reveal shared molecular mechanisms of Helicobacter pylori infection and
Ting Cai1, Xuelin Zhao2, Hai Hu3
1Department of Gastroenterology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China.
Background:
Helicobacter pylori ( H. pylori ), a Group 1 carcinogen, is linked to gastritis, gastric cancer, and extragastric diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), primary Sjögren syndrome (pSS), and systemic sclerosis (SSc). Despite these epidemiological associations, the molecular mechanisms underlying their comorbidity remain unclear.
Materials And Methods:
Integrated transcriptomics were used to identify differentially expressed genes (DEGs) shared between H. pylori and rheumatic diseases, functional enrichment analysis and molecular docking were performed, and hub genes, predicted regulatory transcription factors, and small-molecule drugs were identified.
Results:
We identified DEGs shared between H. pylori infection and rheumatic diseases, namely 134 (RA), 103 (SLE), 244 (pSS), and 75 (SSc). Functional enrichment revealed the following convergent pathways across diseases: immune activation (in RA and pSS), viral defense (in SLE and SSc), and dysregulated Toll-like/NOD-like receptor signaling. Based on the highest degree scores, hub gene screening prioritized CXCL10, JUN (RA); STAT1, CXCL10, ISG15, and MX1 (SLE); PTPRC, ITGB2, CD19, STAT1, and CXCL10 (pSS); and STAT1, CXCL10, MX1, and OAS1 (SSc). Immune infiltration demonstrated disease-specific dysregulation: M1 macrophages in RA/pSS, monocytes in SLE, and T-cell subsets in SSc. Transcription factor analysis revealed STAT1, RELA, and IRFs to be key regulators, as validated in disease datasets. Drug prediction and molecular docking revealed geldanamycin (targeting IGF1R and JUN in RA), oestriol (OAS family and ISG15 in SLE), atorvastatin (CXCL10 and TLR4 in pSS), and cerivastatin ( TLR4 in SSc) as potential therapeutics.
Conclusion:
This study revealed the immune/viral pathways and hub genes linking H. pylori to rheumatic diseases, suggesting potential therapeutic targets.
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:28Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:11Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...